Search Results 221-230 of 2497 for 2024embarking
The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ ...
Mayo Clinic Graduate School of Biomedical Sciences announced in March, 2020 that the competitive grant renewal proposal for its Post-baccalaureate Research ...
Minnesota - 2024 Archives · a microscopic slide of glioblastoma brain cancer cells.
The purpose of this study is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA ...
The purpose of this study is to investigate the effect of CK-2127107 versus placebo on skeletal muscle fatigue assessed as change from baseline versus 14 days ...
Eight eligible Mayo Clinic hospitals earned A grades from The Leapfrog Group, an independent national nonprofit organization that provides safety ratings. All ...
A Study to Evaluate The Effectiveness and Safety of Abrocitinib, with or without Topical Medications, in Subjects Aged 12 Years and Older with Moderate-to- ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
ROCHESTER, Minn. — At Mayo Clinic, researchers published more than 10,000 scientific papers in 2024 that are driving medical discoveries, leading to new ...
This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.